Neurocrine Biosciences· @neurocrine · X·· 2026-08-04AI 评分20
AI 导读
我们近期公布了2026年第二季度财务业绩，重点介绍了我们商业产品组合的强劲表现以及临床管线的进展。 阅读更多：https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-reports-second-quarter-2026-financial
正文
We recently shared our Q2 2026 financial results, highlighting the strength of our commercial portfolio and the progress of our clinical pipeline.
Read more here: https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-reports-second-quarter-2026-financial
来源：Neurocrine Biosciences · x.com